Compassionate Use of Mirdametinib for Individual Patients

Sponsor: SpringWorks Therapeutics, Inc.

Expanded Access
Sponsor score: 60
Inactive

ClinicalTrials ID:NCT05028166

Provider View

This program allows individual patients with serious medical conditions to access Mirdametinib when no other treatment options are available. Approval is needed from the company, ethics boards, and relevant authorities.

Patient Parameters

Program Overview

This program provides access to Mirdametinib for patients who have serious or life-threatening conditions and cannot be treated with existing medications or standard treatments. Each case is considered individually, and the program requires approval from the company, ethics committees, and relevant health authorities.

Eligibility Criteria

Inclusion Criteria

  • The patient has a serious, debilitating, or life-threatening condition that cannot be treated with available medications or standard treatments.
  • The patient has tried all other treatment options without success.
  • The patient is not eligible to join any ongoing clinical trials.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.